In the pediatric Swiss IBD cohort, EIM occurred in 16.7 % of patients with IBD, and these patients were significantly more likely to be treated with anti-TNF-alpha agents than those without EIM (9). The gene discussed is TNF; the disease is inflammatory bowel disease.